<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01831544</url>
  </required_header>
  <id_info>
    <org_study_id>HW-MVAD-01</org_study_id>
    <nct_id>NCT01831544</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the HeartWare MVAD® System (MVAdvantage)</brief_title>
  <official_title>Multi Center, Prospective, Non-Randomized, Single-Arm Trial Evaluating the Clinical Safety and Performance Of the HeartWare MVAD® System For the Treatment of Advanced Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This multi-center, prospective, non-randomized, single-arm trial will investigate the safety&#xD;
      and performance of the HeartWare® Miniaturized Ventricular Assist Device (MVAD®) system over&#xD;
      24 months in subjects with advanced heart failure&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This multi-center, prospective, non-randomized, single-arm trial will investigate the safety&#xD;
      and performance of the Miniaturized Ventricular Assist Device (MVAD®) system over 24 months&#xD;
      in subjects with advanced heart failure. The primary endpoint is survival at 6 months&#xD;
      presented as a simple proportion (subjects alive on the MVAD® pump divided by endpoint&#xD;
      eligible subjects). Secondary endpoints include the incidence of bleeding, incidence of major&#xD;
      infections (per INTERMACS definitions), time to death, incidence of all device failures and&#xD;
      device malfunctions, Health Status improvement, and Functional status improvement. Safety&#xD;
      measures will include the frequency and rates of adverse events, overall and for each&#xD;
      specific event, which will be collected throughout VAD support.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2015</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Actual">May 2, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>Six month</time_frame>
    <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Two years</time_frame>
    <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Overall Survival (Time to Death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Bleeding</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of major bleeding, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of All Device Failures and Device Malfunctions</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of all device failures and device malfunctions per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Major Infection</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of major infection, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neurological Dysfunction</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Incidence of neurological dysfunction per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional Status Change, as Measured by NYHA and 6-minute Walk</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Functional status change, as measured by NYHA and 6-minute walk&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Rates of Adverse Events(AEs)</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Operative Time and Initial Hospital Stay</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Length of operative time and initial hospital stay&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-Hospitalizations</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Re-Hospitalizations, excluding planned procedures&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplantations</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Transplantations&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explants</measure>
    <time_frame>Six month and two years</time_frame>
    <description>Explants&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>MVAD® Pump</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implant of HeartWare MVAD® System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartWare MVAD® System</intervention_name>
    <description>The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
    <arm_group_label>MVAD® Pump</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be ≥18 years of age at consent&#xD;
&#xD;
          2. Subjects with advanced heart failure symptoms (Class IIIB or IV) who meet one of the&#xD;
             following):&#xD;
&#xD;
               1. on optimal medical management including dietary salt restriction and diuretics,&#xD;
                  for at least 45 out of the last 60 days and are failing to respond; or&#xD;
&#xD;
               2. in Class III or Class IV heart failure for at least 14 days and dependent on&#xD;
                  intra-aortic balloon pump (IABP) and/or inotropes.&#xD;
&#xD;
          3. Left ventricular ejection fraction ≤25%.&#xD;
&#xD;
          4. Female subjects of childbearing potential must agree to use adequate contraceptive&#xD;
             precautions (defined as oral contraceptives, intrauterine devices, surgical&#xD;
             contraceptives or a combination of condom and spermicide) for the duration of the&#xD;
             study.&#xD;
&#xD;
          5. The subject has signed the informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Body Mass Index (BMI) &gt; 47.&#xD;
&#xD;
          2. Body Surface Area (BSA) &lt; 1.0 m2.&#xD;
&#xD;
          3. Partial or full mechanical circulatory support within thirty days of implant.&#xD;
&#xD;
          4. Existence of any ongoing mechanical circulatory support (MCS) other than an&#xD;
             intra-aortic balloon pump (IABP) or TandemHeart PTVA®.&#xD;
&#xD;
          5. Prior cardiac transplant or cardiomyoplasty.&#xD;
&#xD;
          6. History of confirmed, untreated abdominal or thoracic aortic aneurysm (diameter &gt; 5&#xD;
             cm).&#xD;
&#xD;
          7. Acute myocardial infarction within 14 days of implant as diagnosed by ST or T wave&#xD;
             changes on the electrocardiogram (ECG), diagnostic biomarkers, ongoing pain and&#xD;
             hemodynamic abnormalities.&#xD;
&#xD;
          8. On ventilator support for &gt; 72 hours within the four days immediately prior to&#xD;
             implant.&#xD;
&#xD;
          9. Pulmonary embolus within three weeks of implant as documented by computed tomography&#xD;
             (CT) scan or nuclear scan.&#xD;
&#xD;
         10. Symptomatic cerebrovascular disease, stroke within 180 days of implant or &gt; 80%&#xD;
             stenosis of carotid or cranial vessels in the absence of confirmed collateral&#xD;
             circulation&#xD;
&#xD;
         11. Uncorrected moderate to severe aortic insufficiency.&#xD;
&#xD;
         12. Severe right ventricular failure as defined by the anticipated need for extracorporeal&#xD;
             membrane oxygenation (ECMO) at the time of screening.&#xD;
&#xD;
         13. Active, uncontrolled infection diagnosed by a combination of clinical symptoms and&#xD;
             laboratory testing, including but not limited to, continued positive cultures,&#xD;
             elevated temperature and white blood cell (WBC) count, hypotension, tachycardia,&#xD;
             generalized malaise despite appropriate antibiotic, antiviral or antifungal treatment.&#xD;
&#xD;
         14. Uncorrected thrombocytopenia or generalized coagulopathy (e.g., platelet count &lt;&#xD;
             75,000, International Normalized Ratio (INR) &gt; 2.0 or Partial Thromboplastin Time&#xD;
             (PTT) &gt; 2.5 times control in the absence of anticoagulation therapy).&#xD;
&#xD;
         15. Intolerance to anticoagulant or antiplatelet therapies or any other peri- or&#xD;
             postoperative therapy that the investigator may administer based upon the subject's&#xD;
             health status.&#xD;
&#xD;
         16. Serum creatinine &gt; 3.0 mg/dL within 72 hours of implant or requiring dialysis.&#xD;
&#xD;
         17. Specific liver enzymes [Aspartate Aminotransferase (AST) (SGOT), and Alanine&#xD;
             Aminotransferase (ALT) (SGPT)] &gt; 3 times upper limit of normal within 72 hours of&#xD;
             implant.&#xD;
&#xD;
         18. A total bilirubin &gt; 3 mg/dL within 72 hours of implant, or biopsy proven liver&#xD;
             cirrhosis or portal hypertension.&#xD;
&#xD;
         19. Pulmonary vascular resistance (PVR) is demonstrated to be unresponsive to&#xD;
             pharmacological manipulation.&#xD;
&#xD;
         20. Subjects with a mechanical heart valve.&#xD;
&#xD;
         21. Etiology of heart failure is due to, or associated with, uncorrected thyroid disease,&#xD;
             obstructive cardiomyopathy, pericardial disease, amyloidosis, active myocarditis or&#xD;
             restrictive cardiomyopathy.&#xD;
&#xD;
         22. History of severe COPD or severe restrictive lung disease (e.g. FEV1 &lt; 50% predicted&#xD;
             value).&#xD;
&#xD;
         23. Participation in any other trial involving investigational drugs or devices within 4&#xD;
             weeks prior to screening and last visit of the trial.&#xD;
&#xD;
         24. Severe illness, other than heart disease, which would limit survival to &lt; 3 years.&#xD;
&#xD;
         25. Peripheral vascular disease with rest pain or ischemic ulcers of the extremities.&#xD;
&#xD;
         26. Pregnancy and breast feeding.&#xD;
&#xD;
         27. Psychiatric disease, irreversible cognitive dysfunction or psychosocial issues that&#xD;
             are likely to impair compliance with the CIP and LVAD.&#xD;
&#xD;
         28. Subject unwilling or unable to comply with trial requirements.&#xD;
&#xD;
         29. Technical obstacles, which pose an inordinately high surgical risk, in the judgment of&#xD;
             the investigator.&#xD;
&#xD;
         30. Employees of the investigator or trial site, with direct involvement in this trial or&#xD;
             other trials under the direction of the investigator or trial site, as well as family&#xD;
             members or employees of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Vincents Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University AKH Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospitalier Pitié-Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Heart and Diabetes Center NRW</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>German Heart Institute Berlin DHZB</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duesseldorf University Hospital</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Hamburg Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <zip>20245</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover Medical School MHH</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leipzig Heart Center</name>
      <address>
        <city>Leipzig</city>
        <zip>04289</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE77DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Papworth Hospital NHS Foundation</name>
      <address>
        <city>Papworth Everard</city>
        <zip>CB233RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2013</study_first_posted>
  <results_first_submitted>March 24, 2020</results_first_submitted>
  <results_first_submitted_qc>March 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">April 7, 2020</results_first_posted>
  <last_update_submitted>May 28, 2021</last_update_submitted>
  <last_update_submitted_qc>May 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 11, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01831544/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT01831544/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Still on original MVAD device</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="14.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="177.3" spread="6.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73.5" spread="14.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Blood Pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Systolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101" spread="15.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.9" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intermacs Patient Profile</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>1 - Critical cardiogenic shock</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 - Progressive decline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 - Inotrope dependent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 - Resting symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5 - Exertion intolerant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 - Exertion limited</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>7 - Advanced NYHA III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Surface Area</title>
          <units>m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.9" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Survival</title>
        <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
        <time_frame>Six month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Primary Endpoint: survival at 6 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 6 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
        <time_frame>Two years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Survival at 24 months presented as a simple proportion. Transplants, explants for recovery and exchanges (to a device other than the MVAD® pump) prior to 24 month follow-up will be eligible for endpoint analysis, with survival status identified at the time of procedure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Overall Survival (Time to Death)</description>
        <time_frame>Six month and two years</time_frame>
        <population>One participant died</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Overall Survival (Time to Death)</description>
          <population>One participant died</population>
          <units>months</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Bleeding</title>
        <description>Incidence of major bleeding, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Bleeding</title>
          <description>Incidence of major bleeding, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of All Device Failures and Device Malfunctions</title>
        <description>Incidence of all device failures and device malfunctions per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of All Device Failures and Device Malfunctions</title>
          <description>Incidence of all device failures and device malfunctions per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Major Infection</title>
        <description>Incidence of major infection, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Major Infection</title>
          <description>Incidence of major infection, per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Neurological Dysfunction</title>
        <description>Incidence of neurological dysfunction per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Neurological Dysfunction</title>
          <description>Incidence of neurological dysfunction per INTERMACS definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</title>
        <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Health Status Change, as Measured by KCCQ and EuroQol EQ-5D-5L</title>
          <description>Health Status change, as measured by KCCQ and EuroQol EQ-5D-5L&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Functional Status Change, as Measured by NYHA and 6-minute Walk</title>
        <description>Functional status change, as measured by NYHA and 6-minute walk&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Status Change, as Measured by NYHA and 6-minute Walk</title>
          <description>Functional status change, as measured by NYHA and 6-minute walk&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Rates of Adverse Events(AEs)</title>
        <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency and Rates of Adverse Events(AEs)</title>
          <description>Frequency and rates of adverse events(AEs) throughout VAD support per INTERMACS Definition&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Operative Time and Initial Hospital Stay</title>
        <description>Length of operative time and initial hospital stay&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Operative Time and Initial Hospital Stay</title>
          <description>Length of operative time and initial hospital stay&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Re-Hospitalizations</title>
        <description>Re-Hospitalizations, excluding planned procedures&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Re-Hospitalizations</title>
          <description>Re-Hospitalizations, excluding planned procedures&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Transplantations</title>
        <description>Transplantations&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Transplantations</title>
          <description>Transplantations&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Explants</title>
        <description>Explants&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
        <time_frame>Six month and two years</time_frame>
        <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>MVAD® Pump</title>
            <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
          </group>
        </group_list>
        <measure>
          <title>Explants</title>
          <description>Explants&#xD;
Note: No endpoints were reached, so this objective was not analyzed</description>
          <population>No data displayed because Outcome Measure has zero total participants analyzed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion: an average of 20.8 months but up to 2 years post implant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MVAD® Pump</title>
          <description>Implant of HeartWare MVAD® System&#xD;
HeartWare MVAD® System: The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Intermacs 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Major Bleeding</sub_title>
                <counts group_id="E1" events="13" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pericardial Fluid Collection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="11" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Malfunction/Failure</sub_title>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Non-CNS Thromboembolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Intermacs 4.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Arrhythmias</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="27" subjects_affected="7" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Major Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device malfunction/failure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Due to the early suspension of enrollments, the target sample size of 57 was not reached. Fewer than 15 subjects were enrolled, thus no analysis was done.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Methee Schreuder</name_or_title>
      <organization>Medtronic</organization>
      <phone>+31611597388</phone>
      <email>methee.schreuder@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

